SEC Filings

8-K
PERNIX THERAPEUTICS HOLDINGS, INC. filed this Form 8-K on 02/19/2019
Entire Document
 

 

39 $23 $23 $21 $10 $5 $6 87% 85% 84% 88% 93% 93% 80% 82% 84% 86% 88% 90% 92% 94% $0 $10 $20 $30 $40 $50 2017A 2018E 2019E 2020E 2021E 2022E Sales Gross Margin 2017A - 2022E Silenor ® Net Product Sales • Net sales up 11% YTD vs. 2017 driven by favorable year - over - year sales volumes • TRx up 3.1% YTD • Loss of Exclusivity in 2020 will allow for four ( Pernix prohibited from launching authorized generic) generic entrants • Company is actively exploring opportunities to build on the Silenor ® franchise through a potential switch to the OTC setting ($ in millions) Note: Projections are subject to numerous assumptions and risks. Silenor ® Forecast A A B B